Phio Pharmaceuticals Corp. (PHIO)
1.09
-0.04
(-3.54%)
USD |
NASDAQ |
Sep 03, 16:00
1.09
0.00 (0.00%)
After-Hours: 18:26
Phio Pharmaceuticals Research and Development Expense (TTM) : 8.533M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.533M |
| March 31, 2026 | 6.525M |
| December 31, 2025 | 4.618M |
| September 30, 2025 | 4.126M |
| June 30, 2025 | 3.589M |
| March 31, 2025 | 3.381M |
| December 31, 2024 | 3.643M |
| September 30, 2024 | 3.665M |
| June 30, 2024 | 4.829M |
| March 31, 2024 | 5.346M |
| December 31, 2023 | 6.332M |
| September 30, 2023 | 6.939M |
| June 30, 2023 | 7.639M |
| March 31, 2023 | 7.56M |
| December 31, 2022 | 7.012M |
| September 30, 2022 | 7.193M |
| June 30, 2022 | 7.492M |
| March 31, 2022 | 7.851M |
| December 31, 2021 | 8.886M |
| September 30, 2021 | 8.269M |
| June 30, 2021 | 6.718M |
| March 31, 2021 | 5.834M |
| December 31, 2020 | 4.431M |
| September 30, 2020 | 4.276M |
| June 30, 2020 | 4.062M |
| Date | Value |
|---|---|
| March 31, 2020 | 4.429M |
| December 31, 2019 | 4.30M |
| September 30, 2019 | 4.221M |
| June 30, 2019 | 4.017M |
| March 31, 2019 | 4.054M |
| December 31, 2018 | 4.326M |
| September 30, 2018 | 4.586M |
| June 30, 2018 | 5.238M |
| March 31, 2018 | 5.384M |
| December 31, 2017 | 5.37M |
| September 30, 2017 | 5.473M |
| June 30, 2017 | 5.447M |
| March 31, 2017 | 5.457M |
| December 31, 2016 | 5.415M |
| September 30, 2016 | 5.831M |
| June 30, 2016 | 6.101M |
| March 31, 2016 | 6.123M |
| December 31, 2015 | 6.925M |
| September 30, 2015 | 6.764M |
| June 30, 2015 | 6.489M |
| March 31, 2015 | 6.311M |
| December 31, 2014 | 5.68M |
| September 30, 2014 | 5.556M |
| June 30, 2014 | 5.326M |
| March 31, 2014 | 5.356M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Imunon, Inc. | 8.191M |
| Agenus, Inc. | 57.69M |
| Amgen, Inc. | 7.638B |
| Anika Therapeutics, Inc. | 27.45M |
| BioCryst Pharmaceuticals, Inc. | 195.46M |